Roflumilast: The evidence for its clinical potential in the treatment of chronic obstructive pulmonary disease

Core Evidence

Volumn 1, Issue 1, 2005, Pages 23-33

  Wagner, Linda Timm ^a   Kenreigh, Charlotte A ^a   Peter, Doris ^b  

^a MLC Solutions Ltd   (United States)

^b Core Medical Publishing ^*  (United States)

Author keywords

COPD; Evidence; Outcomes; Roflumilast; Treatment

Indexed keywords

AMINOPHYLLINE; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; FENOTEROL; FLUTICASONE; FORMOTEROL; GLUCOCORTICOID; IPRATROPIUM BROMIDE; METHYLPREDNISOLONE; METHYLXANTHINE; OXITROPIUM BROMIDE; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; PREDNISONE; ROFLUMILAST; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE; TRIAMCINOLONE;

ABDOMINAL PAIN; ADRENAL SUPPRESSION; ANTIINFLAMMATORY ACTIVITY; BLURRED VISION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CORTICOSTEROID INDUCED MYOPATHY; COST EFFECTIVENESS ANALYSIS; COUGHING; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DRUG EFFECT; DRUG HALF LIFE; DRUG SYNTHESIS; DRUG TOLERANCE; DRUG USE; DYSPHONIA; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; LUNG FUNCTION; NAUSEA; OSTEOPOROSIS; PEAK EXPIRATORY FLOW; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SEIZURE; SIDE EFFECT; SMOKING CESSATION; SYMPTOMATOLOGY; TACHYCARDIA; THRUSH; TREMOR; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

EID: 33646468700     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Aaron SD, Vandeinheen KL, Clinch JJ, et al. Measurement of short-term changes in dyspnea and disease-specific quality of life following an acute COPD exacerbation. Chest. 2002;121:688-696.
2. Afessa B, Morales I, Scanlon P, Peters S. Prognostic factors, clinical course, and hospital outcome of patients with chronic obstructive pulmonary disease admitted to an intensive care unit for acute respiratory failure. Crit Care Med. 2002;30:1610-1615.
3. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med. 2002;11:59-65.
4. Almagro P, Calbo E, Ochoa de Echaguen A, et al. Mortality after hospitalization for COPD. Chest. 2002;121:1441-1448.
5. Anon. Roflumilast. Drugs R&D. 2004;5:176-181.
6. ATS (American Thoracic Society) and ERS (European Respiratory Society). Standards for the diagnosis and management of patients with chronic obstructive pulmonary disease. Available at: http://www.thoracic.org/copd/pdf/copddoc.pdf (accessed January 18, 2005).
7. Barnes PJ. Theophylline. New perspectives for an old drug. Am J Respir Crit Care Med. 2003;167:813-818.
8. Bateman E, Holmes M, Muir J, Andrae K, Witte S, Bredenbroeker D. Safety profile of roflumilast, a novel selective phosphodiesterase 4 inhibitor, in patients with moderate to severe COPD. Presented at the American Thoracic Society Annual Meeting; May 25: Orlando, FL. Poster number F17; 2004.
9. Bethke T, Hartmann M, Baumgartner A, Eichberger C, Hauns B, Wurst W. The new PDE4 inhibitor roflumilast does not influence cardio-vascular function. Presented at the American Thoracic Society Annual Meeting; San Francisco, CA; 2001.
10. Bethke T, Hartmann M, Zech K, David M, Weimar C, Wurst W. No dose adjustment of roflumilast in patients with severe renal impairment. Presented at the American Thoracic Society Annual Meeting; Atlanta, GA; 2002.
11. Bonay M, Bancal C, Crestani B. The risk/benefit of inhaled corticosteroids in chronic obstructive pulmonary disease. Expert Opin Drug Saf. 2005;4:251-271.
12. Bredenbröker D, Syed J, Leichtl S, Rathgeb F, Wurst W. Safety of once-daily roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, in patients with COPD. Presented at the American Thoracic Society Annual Meeting; Atlanta, GA; 2002.
13. Briggs DD. Chronic obstructive pulmonary disease overview: Prevalence, pathogenesis, and treatment. J Manag Care Pharm. 2004;10 (Suppl S-a):S3-S10.
14. de Torres JP, Pinto-Plata V, Ingenito E, et al. Power of outcome measurements to detect clinically significant changes in pulmonary rehabilitation of patients with COPD. Chest. 2002;121:1092-1098.
15. Desikan R, Mason H, Rupp M, Skehan M. Health-related quality of life and healthcare resource utilization by COPD patients: A comparison of three instruments. Qual Life Res. 2002;11:739-751.
16. Domingo-Salvany A, Lamarca R, Ferer M, et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Resp Crit Care Med. 2002;166:680-685.
17. Fan VS, Curtis JR, Tu S-P, McDonell MB, Fihn SD. Using quality of life to predict hospitalization and mortality in patients with obstructive lung diseases. Chest. 2002;122:429-436.
18. Gamble E, Grootendorst DC, Brightling CE, et al. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;168:976-982.
19. GOLD (Global Initiative for Chronic Obstructive Lung Disease), WHO (World Health Organization), NHLBI (National Heart, Lung and Blood Institute). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Bethesda, MD. Global Initiative for Chronic Obstructive Lung Disease, World Health Organization, National Heart, Lung and Blood Institute; 2004.
20. Halbert R, Isonaka S, George D, Igbal A. Interpreting COPD prevalence estimates. What is the true burden of disease? Chest. 2003;123:1684-1692.
21. Hauns B, Bethke T, Huennemeyer A, Hartmann M, Zech K, Wurst W. Influence of food intake on the pharmacokinetics of roflumilast and its active metabolite roflumilast-n-oxide. Presented at the American Thoracic Society Annual Meeting; Atlanta, GA; 2002.
22. Hauns B, Huennemeyer A, Seiberling M, et al. Pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects after a single, oral dose of 500 meg roflumilast in the morning versus evening. Eur Respir J. 2003;22(Suppl. 45):102s.
23. Hauns B, Huennemeyer A, Duursema L, et al. Lack of pharmacokinetic interaction between roflumilast and concomitant warfarin. Presented at the American Thoracic Society Annual Meeting; May 25: Orlando, FL. Poster number F88; 2004a.
24. Hauns B, Huennemeyer A, Koch M, Manegold A, Zech K, Bethke T. Lack of pharmacokinetic drug interaction between roflumilast and erythromycin. Presented at the American Thoracic Society Annual Meeting; May 25: Orlando, FL. Poster number F87; 2004b.
25. Highland KB, Strange C, Heffner JE. Long-term effects of inhaled corticosteroids on Fev1 in patients with chronic obstructive pulmonary disease. Ann Intern Med. 2003;138:969-973.
26. Huennemeyer A, Bethke T, David M, Westphal K, Siegmund W, Wurst W. No interaction of roflumilast and its active metabolite, roflumilast-n-oxide, with inhaled budesonide. Presented at the American Thoracic Society Annual Meeting; Atlanta, GA; 2002a.
27. Huennemeyer A, Hauns B, Drollmann A, et al. Pharmacokinetics of roflumilast and its active metabolite, roflumilast-n-oxide, is not influenced by smoking. Presented at the American Thoracic Society Annual Meeting; Atlanta, GA; 2002b.
28. Jones P. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J. 2002;19:398-404.
29. Kilduff LP, Neder JA, Pitsiladis YP, et al. Clinical relevance of inter-method differences in fat-free mass estimation in chronic obstructive pulmonary disease. Respiration. 2003;70:585-593.
30. Leichtl S, Syed J, Bredenbroeker D, Rathgeb F, Wurst W. Efficacy of once-daily roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, in chronic obstructive pulmonary disease. Presented at the American Thoracic Society Annual Meeting; Atlanta, GA; 2002.
31. Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet. 2005;365:167-175.
32. Make BJ. Chronic obstructive pulmonary disease: Developing comprehensive management. Respir Care. 2003;48:1225-1234.
33. Manegold A, Hauns B, David M, Zech K, Bethke T, Wurst W. Pharmacokinetic characteristics of roflumilast administered in gradually increasing doses of 500 mcg to 1000 mcg are dose-linear in healthy subjects. Eur Respir J. 2002a;20(Suppl. 38):108s.
34. Manegold A, Huennemeyer A, Zech K, et al. Pharmacokinetics of roflumilast and its active metabolite roflumilast-N-oxide in middle aged and young subjects. Eur Respir J. 2002b;20(Suppl. 38):109s.
35. Miravitlles M, Alvarez-Sala J, Lamarca R, et al. Treatment and quality of life in patients with chronic obstructive pulmonary disease. Qual Life Res. 2002;11:329-338.
36. Murray C, Lopez A. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349:1498-1504.
37. NHLBI (National Heart Lung and Blood Institute). Chronic obstructive pulmonary disease. Available at: http://www.nhlbi.nih.gov/health/public/lung/ other/copd_fact.pdf (accessed January 18, 2005).
38. NICE (National Institute for Health and Clinical Excellence). Chronic obstructive pulmonary disease. Management of chronic obstructive pulmonary disease in primary and secondary care. Available at: http://www.nice.org.uk/pdf/ CG012_niceguideline.pdf (accessed January 18, 2004).
39. O'Donnell O, Muir J, Jenkins C, et al. Roflumilast, a novel, selective phosphodiesterase 4 inhibitor, improves quality of life and lowers exacerbation rate in patients with moderate to severe COPD. Presented at the American Thoracic Society Annual Meeting; Orlando, FL. Poster number J58; 2004a.
40. 6: a useful outcome measure of lung function in COPD as assessed in a large clinical study with roflumilast. Presented at the European Respiratory Society Annual Congress; September 6: Glasgow, Scotland. Poster number 2151; 2004b.
41. Oostenbrink J, Rutten-van Molken M. Resource use and risk factors in high-cost exacerbations of COPD. Respir Med. 2004;98:883-891.
42. OPUS study. Effecf of roflumilast on exacerbation rate in patients with chronic obstructive pulmonary disease. Available at: http://www.clinicaltrials. gov. (accessed January 18, 2005).
43. Pauwels R, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet. 2004;364:613-620.
44. Press release. Additional positive roflumilast data of RECORD study at German Congress for Pneumonology, 2004. Available at: http://www.altanapharma. com/home/site.nsf/files/e_2_news.04-03-12.html.
45. Rabe K, Chapman K, Joubert J, Vetter N, Witte S, Bredenbroeker D. Roflumilast, a novel, selective phosphodiesterase 4 inhibitor, improves lung function in patients with moderate to severe COPD. Presented at the American Thoracic Society Annual Meeting; Orlando, FL. Poster number 509; 2004a.
46. Rabe K, O'Donnell D, Muir J, et al. Roflumilast, an oral, once-daily PDE4 inhibitor, improves lung function and reduces exacerbation rates in patients with COPD. Presented at the European Respiratory Society Annual Congress; September 5: Glasgow, Scotland. Poster number 267; 2004b.
47. Rennard S, Decramer M, Calverley P, et al. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J. 2002;20:799-805.
48. Soto FJ, Hanania NA. Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease. Curr Opin Pulm Med. 2005;11:129-134.
49. Spina D. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs. 2003;63:2575-2584.
50. Sturton G, Fitzgerald M. Phosphodiesterase 4 inhibitors for the treatment of COPD. Chest. 2002;121:192S-196S.
51. Sutherland ER, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2689-2697.
52. Vermiere P. The burden of chronic obstructive pulmonary disease. Respir Med. 2002;96(Suppl. C):S3-S10.
53. Weimar C, Westphal K, Bethke T, et al. No interaction of roflumilast, a new, orally active, selective PDE4 inhibitor, with inhaled salbutamol. Presented at the European Respiratory Society Annual Congress; September 23: Berlin, Germany. Poster number 1059; 2001.
54. WHO (World Health Organization). World Health Report 2002. Available at: http://www.who.int/whr/2002 (accessed January 25, 2005).
55. Wyrwich KW, Fihn SD, Tierney WM, Kroenke K, Babu A, Wolinsky FD. Clinically important changes in health-related quality of life for patients with chronic obstructive pulmonary disease. An expert consensus panel report. J Gen Intern Med. 2003;18:196-202.